IDRSF (Idorsia) Short Interest


IDRSF Idorsia Ltd IDRSF
59 GF Score
Price $7.40
GF Value $3.36
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IDRSF vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Idorsia's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Idorsia's Short Interest distribution charts can be found below:

* The bar in red indicates where Idorsia's Short Interest falls into.


IDRSF
59GF Score
Idorsia Ltd IDRSF
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (IDRSF) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of $7.40 is trading 120.2% above its estimated GF Value™ of $3.36. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for IDRSF:

  • Short Interest:
  • GF Value™: $3.36 vs. price of $7.40 (120.2% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the IDRSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
59GF Score

Get the complete analysis for IDRSF

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.40
Price
$3.36
GF Value